Definitive Contract 75F40120C00123

Award Date 9/29/20
Potential Completion Date 3/31/22
Potential Value $274K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Durham, NC 27708, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to Duke University Office of Research Administration Division for the "Evaluating Fitness-for-Use of Electronic Health Records in Clinical Research" project. The contract has a potential value of $1,269,675.26 and a completion date of December 30, 2022. This contract is not set aside. As the prime contractor, Duke University will provide clinical research and...
Duke University has been awarded a firm fixed price purchase order totaling $22,137 by the Department of Health and Human Services Food and Drug Administration. The contract is for technical expertise in predictive toxicology for drug-induced liver injury to be delivered through April 2025 in Durham, North Carolina. As the prime contractor, Duke University will provide technical expert services through its Office of Research Administration to support the FDA's predictive toxicology programs....
This federal contract was awarded to Duke University by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to support the development and deployment of COVID-19 vaccines under Operation Warp Speed. The $281,376.08 definitive cost-no-fee contract, awarded on September 17, 2021, does not have a set-aside designation. The contract supports research and development activities to advance regulatory science and innovation, which aligns with Duke University's expertise...
This is a $1,206,589.24 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to Duke University's Office of Research Administration Division. The contract is for research and development to quantify patient priorities for clinical evidence on the impact of osseointegrated limb prostheses. This award was made under the FDA's Broad Agency Announcement for regulatory science and innovation research, with no set-aside designation. Duke University has previously received...
Duke University is the prime contractor on a $1,609,333 cost-no-fee definitive contract with the Department of Health and Human Services' Food and Drug Administration to perform research titled "Quantifying Patients' Benefit-Risk Tradeoffs Associated with Percutaneous Revascularization Options for Peripheral Arterial Disease: A Collaborative Effort with the Rapid Pathways Patient Science Working Group." There is no set-aside designation. Major subcontractors include the University of...
This federal contract award was made by the National Institute of Child Health and Human Development, a civilian agency, to Duke University as the prime contractor. The $236,068.40 fixed-price cost contract is for biomedical research and exploratory studies, with a performance period ending on June 30, 2013. Duke University is a private, non-profit educational institution that has extensive experience delivering a wide range of research and development services to federal agencies through both...
This is a $740,997 firm-fixed-price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Duke University for research and development related to digital health technologies for infectious disease monitoring. The contract is not set aside under any small business program. Duke University is a prominent private research university with extensive experience managing federal contracts and grants across scientific and...
This is a definitive federal contract awarded by the U.S. government to Duke University's Office of Research Administration Division as the prime contractor. The $3,252,484.82 contract is for biomedical research and exploratory development services, with no set-aside designation used. The contract appears to be part of a larger indefinite delivery/indefinite quantity (IDIQ) vehicle awarded to Duke by the Centers for Disease Control and Prevention (CDC) to provide clinical research and...
This is a $2,073,232.00 firm fixed price delivery order contract awarded by the Agency for Healthcare Research and Quality (AHRQ), a civilian federal agency, to Duke University. The contract is for ARRA (American Recovery and Reinvestment Act)-funded research to conduct a comparative effectiveness study on therapies for heart failure. This contract was not set aside for any specific socioeconomic group. Duke University's Office of Research Administration Division is the prime contractor, with no...
This federal contract award, valued at $400,734.35, was made by the Defense Health Agency to Duke University, a private non-profit university, for a new research contract. The award does not have a set-aside designation. The contract is a definitive contract of the cost-no-fee pricing type, with a performance period ending on December 29, 2018. Duke University's Office of Research Administration Division is the prime contractor. The award indicates that Duke University has been awarded...

Duke University Office of Research Administration Division was awarded a $274,413 definitive contract by the Department of Health and Human Services Food and Drug Administration to conduct a study using electronic health records to identify and assess adverse events for biologic therapies. The contract aims to develop and validate methodological approaches under the agency's Broad Agency Announcement for the Advanced Research and Development of Regulatory Science, which seeks proposals to advance scientific knowledge across nine key areas in support of the FDA's mission. Performance will occur in Durham, North Carolina over a 15-month period concluding in March 2022. There is no set-aside designation.

Generated 12/29/23, 4:19 PM